Waters

Developed by researchers at the University of Michigan, the software could help drive uptake of ion mobility mass spec within the top-down proteomics field.

The company entered an agreement with JP Morgan Chase that provides a five-year unsecured $300 million term loan and a $1.5 billion revolving facility.

The index gained more than 3 percent, significantly outperforming the Nasdaq Biotechnology Index, but slightly underperforming the Dow and Nasdaq.

Waters experienced some sluggishness in the US market in the quarter, and the firm noted that its pharma business, in particular, had seen a shift toward Europe.

The agreement brings together Biognosys' Spectronaut Pulsar DIA software and Waters' SONAR data-independent acquisition mass spectrometry method.

The company posted Q2 revenues of $558.3 million, up from $536.6 million in Q2 2016 and beating the average Wall Street estimate of $553.1 million.

Waters has obtained a non-exclusive license to the technology, which allows researchers to create internal standard calibration curves for their assays.

As researchers continue to explore uses for DDA and DIA workflows, mass spec advances are enabling both methods to generate larger and more complete data sets.

The approval covers Waters' Acquity UPLC and Acquity UPLC I-Class systems, as well as its Xevo TQD, Xevo TQ-S micro, and Xevo TQ-S mass spectrometers.

With the exception of Thermo Fisher Scientific, which released three new instruments, vendors focused mainly on expanded applications of existing platforms.

Pages

The World Health Organization has announced the members of its gene-editing committee, according to NPR.

DARPA is working on developing algorithms that gauge the credibility of research findings, Wired reports.

The American Society of Breast Surgeons recommends all women diagnosed with breast cancer be offered genetic testing, the Washington Post says.

In Science this week: comparison of modern, historical rabbit exomes uncovers parallel evolution after myxoma virus exposure; and more.